Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rozanolixizumab Long-term Safety in ITP (China cohort of TP0004)
CTR20211469Phase 3Completed
- Sponsor
- UCB
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of rozanolixizumab in immune thrombocytopenia (ITP), sponsored by UCB. Started Jul 2021; status: completed.
02
Drugs
rozanolixizumab
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on CTR20211469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211469.